Who are Biotheryx's investors?

Biotheryx's investors include Lumira Ventures, Revelation Partners, SR One Capital Management.

How much funding has Biotheryx raised?

Biotheryx has disclosed $93.8M raised across 4 rounds.

Where is Biotheryx headquartered?

Biotheryx is headquartered in San Diego, US.

Biotheryx

San Diego, US · Founded 2008 · California corporation · 27 employees on LinkedIn · 3 known investors

Find your way into Biotheryx

207 people in our graph share verified history with the Biotheryx team — schools, employers, funds. One of them is your warm intro.

Chris Bischoffunlockedknows Philippe Drouet · together at INSEAD (overlapped)

×3knows the team · via McGill University

×2knows the team · via INSEAD

knows the team · via University of Medicine and Dentistry of New Jersey -New Jersey Medical School

knows the team · via CRISPR

×3knows the team · via Novartis Canada

Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease. Its drug discovery work is built on modulating Cereblon and its proprietary PRODEGY platform.

Biotech Deep Tech Medical Devices

Founders & leadership

Kyle Chan, PhDExecutive

Lawrence ZaslowinPresidentformer

Frank Mercurio, PhDExecutive

Leah FunginChief Executive Officer & Board Member (former Chief Scientific Officer)

Raymond W. Urbanski inActing Chief Medical OfficerRaymond W. Urbanski holds an MD and PhD in Pharmacology from New Jersey Medical School and has spent over 25 years in clinical research, medical practice, and pharmaceutical development, including roles as Chief Medical Officer at GT Biopharma and MannKind Corporation, SVP of Clinical Development at Soleno Therapeutics, and positions at Pfizer spanning oncology clinical research and established products.

Philippe Drouet inChief Executive OfficerPhilippe Drouet held the position of Chief Commercial Officer at CRISPR Therapeutics, where he oversaw commercial strategy and organization development. He is now CEO of Biotheryx, a clinical-stage biopharmaceutical company developing targeted protein degraders for cancer and inflammatory disease.

David Stirling, PhDNamed on SEC filing

Board

Louis DeGennaro, PhDBoard director

Investors · 3

Lumira Ventures✓ verifiedToronto · $1M – $10M

Revelation Partners✓ verifiedSausalito · $5M – $50M

SR One Capital ManagementRedwood City

Reported raises · per SEC filings

Form D private placements

$93.8M disclosed across 4 rounds · 2014–2021

▶$92.1MraisedJun 2021 · 40 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kyle W.H. ChanExecutive Officer
Dung ThaiExecutive Officer
Jack NoelkeDirector
Christopher DevineDirector
Jaime A. DonadioExecutive Officer
Louis DeGennaroDirector
David I. StirlingExecutive Officer, Director
Frank MercurioExecutive Officer
Robert F. WilliamsonExecutive Officer, Director

Offering amount: $100M
Amount sold: $92.1M
First sale: May 2021
Incorporated: Corporation, California
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$500KraisedMay 2015 · 4 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Kyle Chan, PhDExecutive Officer
David Stirling, PhDExecutive Officer, Director
Louis DeGennaro, PhDDirector
Lawrence ZaslowExecutive Officer, Director
Frank Mercurio, PhDExecutive Officer

Offering amount: $6M
Amount sold: $500K
Minimum investment: $50K
First sale: Apr 2015
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$150KraisedSep 2014 · 3 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Louis DeGennaro, PhDDirector
Frank Mercurio, PhDExecutive Officer
Kyle Chan, PhDExecutive Officer
Lawrence ZaslowExecutive Officer, Director
David Stirling, PhDExecutive Officer, Director

Offering amount: $6M
Amount sold: $150K
Minimum investment: $25K
First sale: Sep 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$1MraisedJun 2014 · 10 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Frank Mercurio, PhDExecutive Officer
Lawrence ZaslowExecutive Officer, Director
David Stirling, PhDExecutive Officer, Director
Louis DeGennaro, PhDDirector
Kyle Chan, PhDExecutive Officer

Offering amount: $5M
Amount sold: $1M
Minimum investment: $50K
First sale: May 2014
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Bioworld12 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Nurix Therapeutics9 shared keywordsNurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.

Ultragenyx8 shared keywordsUltragenyx is a biotechnology company focused on developing treatments for patients living with rare genetic diseases. The company emphasizes a culture of generosity, curiosity, and inclusion among its team members.

Exelixis8 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.

Companies competing with Biotheryx for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Biotheryx do?: Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease. Its drug discovery work is built on modulating Cereblon and its proprietary PRODEGY platform.
Who are Biotheryx's investors?: Biotheryx's investors include Lumira Ventures, Revelation Partners, SR One Capital Management.
How much funding has Biotheryx raised?: Biotheryx has disclosed $93.8M raised across 4 rounds.
Where is Biotheryx headquartered?: Biotheryx is headquartered in San Diego, US.